TREE NEWS reports: Novo Nordisk CEO Mike Doustdar said the company is open to upgrading its New York listing to a direct listing as it seeks to raise its profile in the US, though no active discussions are underway. Doustdar sees advantages in replacing Novo Nordisk’s ADR with a direct listing on the New York Stock Exchange, following a similar move by AstraZeneca earlier this year.
Novo Nordisk Open to Direct NYSE Listing, CEO Says
AI take
The signal here is optionality, not action: Novo Nordisk is flagging a structural change to its US market access without committing to one. AstraZeneca's move gives the idea a template, but the absence of active discussions keeps this firmly in the exploratory category. What matters is whether a direct listing would meaningfully shift Novo's US investor base or visibility, given it already trades in New York via ADR. Whether the company moves from openness to formal steps is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
5m ago
South Korea’s Lee Jae Myung Calls for Quick Restart of US-North Korea Talks
7m ago
Swiss upper house backs 90% CET1 guarantee for UBS overseas subsidiaries
12m ago
Chinese Premier Li Qiang Opens 2026 World Skills Conference in Shanghai
13m ago
US Diesel Export Ban Would Tighten Global Supply, Kpler Warns
13m ago
China’s National Energy Administration Urges Larger Energy Investment, Faster Major Projects
15m ago
China’s ChiNext Index Falls 0.6% as PCB Stocks Rally on Thin Volume